Dr. Martens (LON:DOCS) Insider Buys £151.11 in Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson purchased 219 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was purchased at an average price of GBX 69 per share, for a total transaction of £151.11.

Giles Wilson also recently made the following trade(s):

• On Tuesday, January 13th, Giles Wilson acquired 192 shares of Dr. Martens stock. The shares were acquired at an average price of GBX 78 per share, with a total value of £149.76.
• On Thursday, December 11th, Giles Wilson acquired 197 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 76 per share, with a total value of £149.72.

Dr. Martens Stock Up 1.6%

DOCS opened at GBX 68.35 on Friday. The stock’s 50 day moving average price is GBX 74.09 and its 200 day moving average price is GBX 82.27. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The stock has a market cap of £660.66 million, a P/E ratio of 40.21, a P/E/G ratio of 6.40 and a beta of 0.11. Dr. Martens plc has a 12 month low of GBX 43.02 and a 12 month high of GBX 100.87.

Dr. Martens (LON:DOCS) last announced its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, research analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DOCS. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a research report on Tuesday, January 27th. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating on shares of Dr. Martens in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Dr. Martens currently has a consensus rating of “Moderate Buy” and an average price target of GBX 6,000.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.